Cantor Fitzgerald Stands Firm: Eli Lilly’s Rating Reaffirmed – What’s Next for LLY.US
- Cantor Fitzgerald has reaffirmed its "overweight" rating for Eli Lilly (LLY.US) and adjusted the target price from $885.00 to $885.00.
- Eli Lilly is a pharmaceutical company engaged in the discovery, development, manufacture, and sale of drugs.
- The human drug products division includes the discovery, development, manufacture, marketing, and sale of global human drug products in various therapeutic areas, such as:
Eli Lilly (LLY.US) Rating Reaffirmed by Cantor Fitzgerald
Cantor Fitzgerald has reaffirmed its “overweight” rating for Eli Lilly (LLY.US) and adjusted the target price from $885.00 to $885.00.
About Eli Lilly
Eli Lilly is a pharmaceutical company engaged in the discovery, development, manufacture, and sale of drugs. The company operates through two main business segments: human drugs and animal health products.
Human Drug Products
The human drug products division includes the discovery, development, manufacture, marketing, and sale of global human drug products in various therapeutic areas, such as:
- Neuroscience
- Endocrinology
- Oncology
- Cardiovascular disease
- Others
Animal Health Products
The animal health products division operates through the Elanco Animal Health Division, which develops, produces, and sells food and companion animal products. Some of the notable animal health products include:
- Livestock and poultry products: Rumensin, Taylan, Posilac, Paylean
- Companion animal products: Trifexis, Comfortis
Company Overview
Eli Lilly was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, Indiana.